JP2002536018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002536018A5 JP2002536018A5 JP2000598639A JP2000598639A JP2002536018A5 JP 2002536018 A5 JP2002536018 A5 JP 2002536018A5 JP 2000598639 A JP2000598639 A JP 2000598639A JP 2000598639 A JP2000598639 A JP 2000598639A JP 2002536018 A5 JP2002536018 A5 JP 2002536018A5
- Authority
- JP
- Japan
- Prior art keywords
- glycosylated
- seq
- protein
- nucleic acid
- glycosylated leptin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical class O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 39
- 210000004027 cells Anatomy 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 14
- 230000003899 glycosylation Effects 0.000 description 9
- 238000006206 glycosylation reaction Methods 0.000 description 9
- 229920001850 Nucleic acid sequence Polymers 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 5
- 102000016267 Leptin Human genes 0.000 description 5
- 108010092277 Leptin Proteins 0.000 description 5
- 102000035443 Peptidases Human genes 0.000 description 5
- 108091005771 Peptidases Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 229940039781 leptin Drugs 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 235000019833 protease Nutrition 0.000 description 5
- 102000035362 glycosylated proteins Human genes 0.000 description 4
- 108091005600 glycosylated proteins Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 2
- -1 CD11α Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 125000001235 proline group Chemical group [H]N1[C@@](C(=O)[*])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 102100006077 CP Human genes 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 229960000301 Factor VIII Drugs 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090000467 Interferon beta Proteins 0.000 description 1
- 102000003996 Interferon beta Human genes 0.000 description 1
- 229940029329 Intrinsic factor Drugs 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229940040608 SPS Drugs 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100019017 VWF Human genes 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 229960001134 von Willebrand factor Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24967599A | 1999-02-12 | 1999-02-12 | |
| US09/249,675 | 1999-02-12 | ||
| PCT/US2000/003652 WO2000047741A1 (en) | 1999-02-12 | 2000-02-11 | Glycosylated leptin compositions and related methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002536018A JP2002536018A (ja) | 2002-10-29 |
| JP2002536018A5 true JP2002536018A5 (ru) | 2006-11-30 |
| JP4841037B2 JP4841037B2 (ja) | 2011-12-21 |
Family
ID=22944511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000598639A Expired - Fee Related JP4841037B2 (ja) | 1999-02-12 | 2000-02-11 | グリコシル化レプチン組成物および関連する方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1151102B1 (ru) |
| JP (1) | JP4841037B2 (ru) |
| AT (1) | ATE323766T1 (ru) |
| AU (1) | AU781460B2 (ru) |
| CA (1) | CA2359840C (ru) |
| CY (1) | CY1107470T1 (ru) |
| DE (1) | DE60027409T2 (ru) |
| DK (1) | DK1151102T3 (ru) |
| ES (1) | ES2257287T3 (ru) |
| PT (1) | PT1151102E (ru) |
| WO (1) | WO2000047741A1 (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| EP1420812A1 (en) * | 2001-08-29 | 2004-05-26 | The University of Buckingham | Use of leptin for infant with low birth weight for prevention of obesity |
| ES2418954T3 (es) * | 2001-10-22 | 2013-08-19 | Amgen, Inc. | Uso de la leptina para el tratamiento de la lipoatrofia humana y método para determinar la predisposición a dicho tratamiento |
| US7094579B2 (en) * | 2002-02-13 | 2006-08-22 | Xoma Technology Ltd. | Eukaryotic signal sequences for prokaryotic expression |
| US20040248262A1 (en) | 2003-01-22 | 2004-12-09 | Koeberl Dwight D. | Constructs for expressing lysomal polypeptides |
| ATE448312T1 (de) | 2003-09-26 | 2009-11-15 | Merck Serono Sa | Leitsequenzen zur verwendung bei der produktion von proteinen |
| US20080176790A1 (en) * | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
| WO2008067599A1 (en) * | 2006-12-04 | 2008-06-12 | Apollo Life Sciences Limited | Isolated leptin and adiponectin molecules and chimeric molecules thereof |
| MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
| JP2009126856A (ja) * | 2007-11-28 | 2009-06-11 | Fancl Corp | 血中中性脂肪上昇抑制剤 |
| JP5622720B2 (ja) | 2008-05-21 | 2014-11-12 | ニューロテスインコーポレイテッド | 神経原繊維変化に関連する進行性認知障害の治療方法 |
| WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| KR20120024529A (ko) | 2008-11-04 | 2012-03-14 | 니콜라오스 테자프시디스 | 신경섬유 매듭 및 아밀로이드 베타의 축적으로부터 기인하는 진행성 인지 기능 장애의 치료용 렙틴 조성물 및 치료 방법 |
| CA2813038C (en) | 2010-09-28 | 2021-12-28 | Amylin Pharmaceuticals, Llc | Highly soluble leptins |
| CA3062003C (en) | 2012-05-17 | 2022-01-11 | Extend Biosciences, Inc. | Vitamin d as a targeting group for therapeutic peptides |
| EP2900230B1 (en) | 2012-09-27 | 2018-08-15 | The Children's Medical Center Corporation | Compounds for the treatment of obesity and methods of use thereof |
| ES2709976T3 (es) | 2013-11-26 | 2019-04-22 | Childrens Medical Ct Corp | Compuestos para el tratamiento de la obesidad y procedimientos de uso de los mismos |
| WO2015153933A1 (en) | 2014-04-03 | 2015-10-08 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| EP3481413A4 (en) * | 2016-07-08 | 2020-01-08 | Askgene Pharma, Inc. | FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| BR112019004715A2 (pt) | 2016-09-12 | 2019-07-16 | Aegerion Pharmaceuticals Inc | métodos para detectar anticorpos neutralizantes anti-leptina |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5326700A (en) * | 1990-11-06 | 1994-07-05 | Eli Lilly And Company | DNA sequences encoding t-PA derivatives with cleavable sites |
| IL192290A0 (en) * | 1993-08-17 | 2008-12-29 | Kirin Amgen Inc | Erythropoietin analogs |
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| AU4766596A (en) * | 1995-01-31 | 1996-08-21 | Eli Lilly And Company | Ob gene product antibodies |
| CA2358862A1 (en) * | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| AU1406497A (en) * | 1995-12-06 | 1997-06-27 | Schering Corporation | Mutational variants of mammalian ob gene proteins |
| JPH09176198A (ja) * | 1995-12-28 | 1997-07-08 | Kikkoman Corp | 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ |
| WO1997026916A1 (en) * | 1996-01-25 | 1997-07-31 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
| EP0827750A3 (en) * | 1996-08-23 | 2002-11-20 | Eli Lilly And Company | Obesity protein formulations |
| AU1208599A (en) * | 1997-10-31 | 1999-05-24 | Eli Lilly And Company | Glycosylated obesity protein analogs |
| WO2000009165A1 (en) * | 1998-08-10 | 2000-02-24 | Amgen Inc. | Dextran-leptin conjugates, pharmaceutical compositions and related methods |
| US6420339B1 (en) * | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
-
2000
- 2000-02-11 CA CA2359840A patent/CA2359840C/en not_active Expired - Fee Related
- 2000-02-11 EP EP00911784A patent/EP1151102B1/en not_active Expired - Lifetime
- 2000-02-11 DE DE60027409T patent/DE60027409T2/de not_active Expired - Lifetime
- 2000-02-11 JP JP2000598639A patent/JP4841037B2/ja not_active Expired - Fee Related
- 2000-02-11 ES ES00911784T patent/ES2257287T3/es not_active Expired - Lifetime
- 2000-02-11 PT PT00911784T patent/PT1151102E/pt unknown
- 2000-02-11 AT AT00911784T patent/ATE323766T1/de active
- 2000-02-11 WO PCT/US2000/003652 patent/WO2000047741A1/en active IP Right Grant
- 2000-02-11 AU AU33623/00A patent/AU781460B2/en not_active Ceased
- 2000-02-11 DK DK00911784T patent/DK1151102T3/da active
-
2006
- 2006-07-07 CY CY20061100939T patent/CY1107470T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002536018A5 (ru) | ||
| CA2359840A1 (en) | Glycosylated leptin compositions and related methods | |
| Kontermann | Half-life extended biotherapeutics | |
| Doherty et al. | Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor | |
| JP6983075B2 (ja) | 極性の組換え延長部を有するインスリン | |
| CN102164949B (zh) | 新型重组融合蛋白 | |
| CA2288992A1 (en) | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof | |
| RU2007132188A (ru) | Конъюгаты биологически активных белков, имеющие модифицированное время полужизни in vivo | |
| JP4156024B2 (ja) | 修飾されたタンパク質及びペプチド医薬品 | |
| CA2304254A1 (en) | Trimerising module | |
| ATE169959T1 (de) | Anthrax-toxin-fusionsproteine und deren verwendungen | |
| JP2011501951A5 (ru) | ||
| WO2014165093A2 (en) | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto | |
| Huang et al. | Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-α2b fusion protein expressed in Pichia pastoris | |
| WO1993006228A1 (en) | A new form of liposaccharide binding protein (lbp) | |
| EP3642338B1 (en) | Fusion protein with half-life extending polypeptide | |
| JP2008543304A (ja) | ヒト顆粒球コロニー刺激因子イソ型（ＨｕｍａｎＧｒａｎｕｌｏｃｙｔｅ−ＣｏｌｏｎｙＳｔｉｍｕｌａｔｉｎｇＦａｃｔｏｒＩｓｏｆｏｒｍｓ） | |
| CN103641896B (zh) | 明胶样单元的用途 | |
| IL294070A (en) | Mutains of il-2 | |
| CN105524147B (zh) | 重组聚多肽及其应用 | |
| Ji et al. | Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β | |
| US10618970B2 (en) | Method of treating cancer with IL-10 and antibodies that induce ADCC | |
| Buchanan et al. | Novel therapeutic proteins and peptides | |
| CA2565173A1 (en) | Interleukin-11 fusion proteins | |
| CN111944008A (zh) | 一种突变蛋白的方法以及得到的突变体蛋白 |